Switch theme
Sign up to access all valuation multiples
Krka DD engages in the development, production, marketing, and sales of human health products (prescription pharmaceuticals and non-prescription products), animal health products, health resorts, and tourist services. The company products in Prescription pharmaceuticals include Cardiovascular diseases, Infections, and Oncology; Non-prescription products include Cold and cough products, nasal products, vitamins and minerals, and hair care products; and Animal health products include Antimicrobials and disinfectants, among others. It operates across the European Union, South-East Europe, East Europe region, and Others. The company derives a majority of its revenue from the European Union.
1954
11.8K+
LTM Revenue $2.2B
LTM EBITDA $595M
$5.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Krka has a last 12-month revenue (LTM) of $2.2B and a last 12-month EBITDA of $595M.
In the most recent fiscal year, Krka achieved revenue of $2.0B and an EBITDA of $530M.
Krka expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Krka valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.2B | XXX | $2.0B | XXX | XXX | XXX |
| Gross Profit | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 57% | XXX | XXX | XXX |
| EBITDA | $595M | XXX | $530M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $487M | XXX | $447M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 22% | XXX | XXX | XXX |
| Net Profit | $404M | XXX | $353M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Krka's stock price is EUR 184 (or $207).
Krka has current market cap of EUR 5.7B (or $6.4B), and EV of EUR 5.1B (or $5.7B).
See Krka trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.7B | $6.4B | XXX | XXX | XXX | XXX | $13.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Krka has market cap of $6.4B and EV of $5.7B.
Krka's trades at 2.8x EV/Revenue multiple, and 10.8x EV/EBITDA.
Equity research analysts estimate Krka's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Krka has a P/E ratio of 15.7x.
See valuation multiples for Krka and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.4B | XXX | $6.4B | XXX | XXX | XXX |
| EV (current) | $5.7B | XXX | $5.7B | XXX | XXX | XXX |
| EV/Revenue | 2.6x | XXX | 2.8x | XXX | XXX | XXX |
| EV/EBITDA | 9.6x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | 11.8x | XXX | 12.8x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.7x | XXX | 18.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 57.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialKrka's last 12 month revenue growth is 6%
Krka's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Krka's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Krka's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Krka and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Krka acquired XXX companies to date.
Last acquisition by Krka was XXXXXXXX, XXXXX XXXXX XXXXXX . Krka acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Krka founded? | Krka was founded in 1954. |
| Where is Krka headquartered? | Krka is headquartered in Slovenia. |
| How many employees does Krka have? | As of today, Krka has 11.8K+ employees. |
| Is Krka publicy listed? | Yes, Krka is a public company listed on LJU. |
| What is the stock symbol of Krka? | Krka trades under KRKG ticker. |
| When did Krka go public? | Krka went public in 1997. |
| Who are competitors of Krka? | Similar companies to Krka include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Krka? | Krka's current market cap is $6.4B |
| What is the current revenue of Krka? | Krka's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Krka? | Krka revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Krka? | Current revenue multiple of Krka is 2.6x. |
| Is Krka profitable? | Yes, Krka is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Krka? | Krka's last 12 months EBITDA is $595M. |
| What is Krka's EBITDA margin? | Krka's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Krka? | Current EBITDA multiple of Krka is 9.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
